Role of PTK-7 in Acute Myeloid Leukemias (LAM-PTK7)

Institut Paoli-Calmettes

Status: Completed

Conditions: Acute Myeloid Leukemia

Treatments: Other: Blood sampling; Other: Bone marrow aspiration

Study type: Interventional

Funder types: Other

Identifiers

NCT02860793

LAM-PTK7-IPC 2013-011

Details and patient eligibility

About

The pseudo tyrosine kinase receptor 7 (PTK7) is an orphan tyrosine kinase receptor assigned to the planar cell polarity pathway. PTK7 is expressed in normal myeloid progenitors and CD34(+) CD38(-) bone marrow cells in humans. It is also expressed in acute myeloid leukemia (AML) and is mostly assigned to granulocytic lineage differentiation. In AML, PTK7 seems to convey promigratory and antiapoptotic signals into the cell and represents an independent prognosis factor of survival in patients treated with induction chemotherapy. This study aims at:

• evaluating the impact of PTK7 expression on primary AML cells ex vivo
• evaluating the diagnostic and prognostic value of a soluble form of PTK7

Enrollment: 10 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age> 18 years
• AML at diagnosis, not previously treated
• Treatment by induction chemotherapy
• Signed informed consent
• Affiliation to the French social security system

Exclusion criteria

• pregnant woman(or of childbearing potential) or breastfeeding woman
• emergency
• patients deprived of liberty or placed under the authority of a tutor

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

AML patients at diagnosis

Experimental group

Treatment:

Other: Blood sampling

Other: Bone marrow aspiration